Pasar al contenido principal

Identificación y caracterización funcional de variantes genéticas estructurales en pacientes con errores congénitos de la inmunidad.

PI23/00161

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i en Salud
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO DE INVESTIGACION VALLE DE HEBRON
Centro realización INSTITUTO DE INVESTIGACION HOSPITAL UNIVERSITARIO VALLE DE HEBRON (VHIR)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

De Novo or inherited, gonosomal mosaicism in hereditary angioedema due to C1 inhibitor deficiency

  • Batlle-Masó, Laura|||0000-0002-4209-176X
  • Perurena Prieto, Janire|||0000-0002-3048-1058
  • Viñas-Giménez, Laura|||0000-0003-2913-1154
  • Aguiló-Cucurull, Aina|||0000-0001-5622-778X
  • Fernández-Álvarez, Paula|||0000-0003-2695-3531
  • Gil-Serrano, Johana|||0000-0002-0673-7391
  • Guilarte, Mar|||0000-0001-7242-9584
  • Colobrán Oriol, Roger|||0000-0002-5964-536X
Hereditary angioedema (HAE) is a rare genetic disease, characterized by transient and self-limiting episodes of subcutaneous or submucosal swelling that spontaneously resolve within two to five days. The most common form of HAE, HAE-C1-INH, is caused by deleterious mutations in the SERPING1 gene, encoding the C1-Inhibitor protein, and its diagnosis is confirmed by decreased C1-INH function. Distinctively from other genetic forms of HAE, up to 15-20% of HAE-C1-INH cases are sporadic caused by de novo mutations. Here, we report a patient with apparently sporadic HAE-C1-INH. The patient had compatible clinical symptoms and a markedly low C1-INH function, and the parents showed normal values of C4 and normal C1-INH function. In the patient, we identified a novel splice site mutation in SERPING1 (c.890-1G.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Somatic reversion in CD137 deficiency correlating with Epstein-Barr virus control and clinical improvement

  • Batlle-Masó, Laura|||0000-0002-4209-176X
  • Padrosa Pulido, Joan|||0000-0002-3354-5811
  • Esteve-Codina, Anna|||0000-0003-0361-2873
  • Perurena-Prieto, Janire
  • Franco-Jarava, Clara|||0000-0002-9788-189X
  • Aguiló-Cucurull, Aina|||0000-0001-5622-778X
  • Martínez Gallo, Mónica|||0000-0002-7340-2161
  • Cea López, Cristina|||0000-0003-0776-6706
  • Rodriguez-Aliberas, Marta
  • Soler Palacín, Pere|||0000-0002-0346-5570
  • Casals, Ferran|||0000-0002-8941-0369
  • Redondo, Sara|||0000-0001-8967-7410
  • Torrent, Montserrat|||0000-0003-1917-1056
  • Alsina Manrique, Laia|||0000-0002-3559-0018
  • Colobrán Oriol, Roger|||0000-0002-5964-536X
Epstein-Barr virus (EBV) is an oncogenic virus ubiquitous in human populations. CD8 T cells play a crucial role in establishing a strong anti-EBV immune response. Among the various inborn errors of immunity (IEI) showing a restricted vulnerability to EBV, TNFRSF9 (CD137, 4-1BB) deficiency was described in 2019 in patients with chronic EBV viremia and EBV-associated lymphoproliferative diseases. We here investigated a patient with a history of chronic EBV infection and CD137 deficiency who had previously undergone transplantation from her HLA-identical brother. We found that the brother was also a homozygous carrier of the same TNFRSF9 variant, explaining the patient's inability to control EBV after transplantation. Remarkably, during a period of spontaneous clinical improvement and EBV control, we detected two somatic variants in the patient, which resulted in the emergence of two independent revertant CD8 T cell clones that accounted for up to 20% of CD8 T cells in peripheral blood. Using single cell RNA sequencing we demonstrated that both revertant clones originated post-transplant from donor-derived cells. We report here the first described case of a somatic reversion phenomenon in TNFRSF9 deficiency, correlating with clinical improvement and paving the way for future gene therapy strategies for this IEI.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Exploring the strengths and limitations of AI-driven variant prioritization versus manual curation in inborn errors of immunity

  • Moushib, Laith Ibrahim
  • Moreno-Ruiz, Nerea
  • Martín-Nalda, Andrea
  • Rivière, Jacques G
  • Urban, Blanca
  • Dieli-Crimi, Romina
  • Perurena-Prieto, Janire
  • Aguiló-Cucurull, Aina
  • Pérez-Estévez, Elena
  • Solanich, Xavier
  • Soler-Palacín, Pere
  • Colobran, Roger
  • Batlle-Masó, Laura
Next-generation sequencing (NGS) has transformed the genetic diagnosis of human diseases, yet many patients remain unsolved due to the complexity of variant interpretation. Manual curation of candidate variants is effective but time-consuming and requires specialized expertise. Artificial intelligence (AI)-driven platforms have emerged as scalable tools for variant prioritization, yet their performance compared with manual curation remains insufficiently evaluated. The aim of this study was to evaluate the performance of AI-driven platforms for variant prioritization in a cohort of patients with inborn errors of immunity (IEI) and to compare their strengths and limitations with manual curation., The author(s) declared that financial support was received for this work and/or its publication. This study was funded by Instituto de Salud Carlos III, grants PI20/00761 and PI23/00161, co-financed by the European Regional Development Fund (ERDF); and by the Jeffrey Modell Foundation. This research is supported by the European Reference Network for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (ERN-RITA). LM acknowledges support from The Swedish Board of Student Finance (CSN); NM-R was supported by grant 2021 FI_B_00296 from Agència de Gestió d’Ajuts Universitaris i de Recerca, Generalitat de Catalunya; and LB-M is supported by an ISCIII postdoctoral fellowship, “Sara Borrell,” CD24/00011, co-financed by the European Union. Some of the samples were analyzed using the AION platform, supported by the AION Research Grant Program (Nostos) awarded to the Translational Immunology Research Group at VHIR. None of the sponsors has been involved in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the article for publication., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Transmission of F12-related hereditary angioedema through a sperm donor

  • Marquès, Lluís
  • Alcoceba, Eva
  • Lara, Silvia
  • Batlle-Masó, Laura
  • Aguiló Cucurull, Aina
  • Gil Serrano, Ingrid Johana
  • Guilarte, Mar
  • Colobran, Roger
F12 gene; Hereditary angioedema; Sperm donor, Gen F12; Angioedema hereditari; Donant d'esperma, Gen F12; Angioedema hereditario; Donante de esperma, Hereditary angioedema due to F12 pathogenic variants (HAE-FXII) is a rare autosomal dominant disorder characterized by recurrent episodes of angioedema mediated by bradykinin, incomplete penetrance, and marked sex-dependent clinical expression. Most affected individuals carry the recurrent F12 c.983C>A/p.Thr328Lys (T328K) founder variant. Here, we report the first documented transmission of HAE-FXII through sperm donation. The index case was an 18-year-old woman with recurrent estrogen-dependent angioedema, normal C1-inhibitor levels and function, and poor response to conventional antiallergic therapy. Molecular analysis identified the heterozygous F12 T328K variant. Familial investigation revealed the same variant in her asymptomatic twin brother, while their mother tested negative, strongly suggesting paternal transmission. The fertility clinic was contacted, and genetic testing confirmed that the sperm donor was a heterozygous carrier of the F12 T328K variant. Women who had conceived using this donor’s sperm were subsequently notified. Through this process, a second unrelated family was identified, in which a young woman was also found to carry the heterozygous F12 T328K variant and is currently asymptomatic under specialist follow-up. This study provides the first direct evidence of transmission of HAE-FXII through assisted reproductive technologies. Our findings highlight how autosomal dominant disorders with incomplete and sex-dependent penetrance can remain clinically silent in donors and be unknowingly transmitted to multiple offspring. These observations have important implications for genetic counseling, donor notification strategies, and donor screening policies, and support consideration of targeted screening for recurrent pathogenic variants such as F12 T328K in regions where HAE-FXII is more prevalent., The author(s) declared that financial support was received for this work and/or its publication. This study was funded by Instituto de Salud Carlos III, grant PI23/00161, cofinanced by the European Regional Development Fund (ERDF). LB-M is supported by an ISCIII postdoctoral fellowship, “Sara Borrell,” CD24/00011, co-financed by the European Union.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Exploring the strengths and limitations of AI-driven variant prioritization versus manual curation in inborn errors of immunity

  • Moushib, Laith Ibrahim
  • Moreno-Ruiz, Nerea
  • Urban Vargas, Blanca Angélica
  • Aguiló Cucurull, Aina
  • Martin, Andrea
  • Rivière, Jacques G.
  • Dieli-Crimi Vinuesa, Romina
  • Perurena-Prieto, Janire
  • Soler-Palacin, Pere
  • Colobran, Roger
  • Batlle-Masó, Laura
Artificial intelligence; Genetic diagnosis; Inborn errors of immunity, Inteligencia artificial; Diagnóstico genético; Errores congenitos de la inmunidad, Intel·ligència artificial; Diagnòstic genètic; Errors congènits de la immunitat, Introduction: Next-generation sequencing (NGS) has transformed the genetic diagnosis of human diseases, yet many patients remain unsolved due to the complexity of variant interpretation. Manual curation of candidate variants is effective but time-consuming and requires specialized expertise. Artificial intelligence (AI)-driven platforms have emerged as scalable tools for variant prioritization, yet their performance compared with manual curation remains insufficiently evaluated. The aim of this study was to evaluate the performance of AI-driven platforms for variant prioritization in a cohort of patients with inborn errors of immunity (IEI) and to compare their strengths and limitations with manual curation.Methods: We analyzed 22 unsolved IEI cases that had previously undergone inconclusive NGS studies. Whole-genome sequencing was performed, and variant prioritization was carried out using two AI-driven platforms -AIMARRVEL and AION (Nostos Genomics)- and by manual curation. Selected variants were classified according to clinical relevance (very high, high, medium, or low), integrating both molecular and phenotypic evidence.Results: Across the cohort, AI platforms efficiently prioritized variants with clear pathogenic features, often reaching the same conclusions as manual curation but in a fraction of the time. One patient (5%) received a conclusive diagnosis (FAM111B), and four patients (18%) carried variants of high clinical relevance, including strong disease-causing candidates in CD247 and SH2B3. Additional medium-relevance variants were identified in 36% of cases, although evidence was insufficient for functional validation. Notably, concordance between AIMARRVEL and AION was limited, particularly for variants of uncertain significance (VUS), reflecting differences in algorithmic weighting of variant features versus clinical phenotype. Both platforms also highlighted potentially novel associations in RUNX1 and TRAF7, underscoring their capacity to extend beyond classical IEI genes.Discussion: Our results show that AI-driven tools are powerful for detecting clearly pathogenic variants and can markedly accelerate the diagnostic process. However, their strong reliance on curated databases, limited incorporation of phenotypic data, and challenges in handling VUS may reduce their effectiveness. Enhancing phenotype integration, expanding annotations (including non-coding regions), and incorporating up-to-date literature could improve their performance. Ultimately, AI tools should complement expert curation, with future models evolving toward integrative approaches that better capture the complexity of human disorders., The author(s) declared that financial support was received for this work and/or its publication. This study was funded by Instituto de Salud Carlos III, grants PI20/00761 and PI23/00161, co-financed by the European Regional Development Fund (ERDF); and by the Jeffrey Modell Foundation. This research is supported by the European Reference Network for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (ERN-RITA). LM acknowledges support from The Swedish Board of Student Finance (CSN); NM-R was supported by grant 2021 FI_B_00296 from Agència de Gestió d’Ajuts Universitaris i de Recerca, Generalitat de Catalunya; and LB-M is supported by an ISCIII postdoctoral fellowship, “Sara Borrell,” CD24/00011, co-financed by the European Union. Some of the samples were analyzed using the AION platform, supported by the AION Research Grant Program (Nostos) awarded to the Translational Immunology Research Group at VHIR. None of the sponsors has been involved in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Transmission of F12-related hereditary angioedema through a sperm donor

  • Marquès, Lluís
  • Alcoceba, Eva
  • Lara, Silvia
  • Batlle-Masó, Laura
  • Aguiló Cucurull, Aina
  • Gil Serrano, Ingrid Johana
  • Guilarte, Mar
  • Colobran, Roger
F12 gene; Hereditary angioedema; Sperm donor, Gen F12; Angioedema hereditari; Donant d'esperma, Gen F12; Angioedema hereditario; Donante de esperma, Hereditary angioedema due to F12 pathogenic variants (HAE-FXII) is a rare autosomal dominant disorder characterized by recurrent episodes of angioedema mediated by bradykinin, incomplete penetrance, and marked sex-dependent clinical expression. Most affected individuals carry the recurrent F12 c.983C>A/p.Thr328Lys (T328K) founder variant. Here, we report the first documented transmission of HAE-FXII through sperm donation. The index case was an 18-year-old woman with recurrent estrogen-dependent angioedema, normal C1-inhibitor levels and function, and poor response to conventional antiallergic therapy. Molecular analysis identified the heterozygous F12 T328K variant. Familial investigation revealed the same variant in her asymptomatic twin brother, while their mother tested negative, strongly suggesting paternal transmission. The fertility clinic was contacted, and genetic testing confirmed that the sperm donor was a heterozygous carrier of the F12 T328K variant. Women who had conceived using this donor’s sperm were subsequently notified. Through this process, a second unrelated family was identified, in which a young woman was also found to carry the heterozygous F12 T328K variant and is currently asymptomatic under specialist follow-up. This study provides the first direct evidence of transmission of HAE-FXII through assisted reproductive technologies. Our findings highlight how autosomal dominant disorders with incomplete and sex-dependent penetrance can remain clinically silent in donors and be unknowingly transmitted to multiple offspring. These observations have important implications for genetic counseling, donor notification strategies, and donor screening policies, and support consideration of targeted screening for recurrent pathogenic variants such as F12 T328K in regions where HAE-FXII is more prevalent., The author(s) declared that financial support was received for this work and/or its publication. This study was funded by Instituto de Salud Carlos III, grant PI23/00161, cofinanced by the European Regional Development Fund (ERDF). LB-M is supported by an ISCIII postdoctoral fellowship, “Sara Borrell,” CD24/00011, co-financed by the European Union.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Exploring the strengths and limitations of AI-driven variant prioritization versus manual curation in inborn errors of immunity

  • Moushib, Laith Ibrahim
  • Moreno-Ruiz, Nerea
  • Urban Vargas, Blanca Angélica
  • Aguiló Cucurull, Aina
  • Martin, Andrea
  • Rivière, Jacques G.
  • Dieli-Crimi Vinuesa, Romina
  • Perurena-Prieto, Janire
  • Soler-Palacin, Pere
  • Colobran, Roger
  • Batlle-Masó, Laura
Artificial intelligence; Genetic diagnosis; Inborn errors of immunity, Inteligencia artificial; Diagnóstico genético; Errores congenitos de la inmunidad, Intel·ligència artificial; Diagnòstic genètic; Errors congènits de la immunitat, Introduction: Next-generation sequencing (NGS) has transformed the genetic diagnosis of human diseases, yet many patients remain unsolved due to the complexity of variant interpretation. Manual curation of candidate variants is effective but time-consuming and requires specialized expertise. Artificial intelligence (AI)-driven platforms have emerged as scalable tools for variant prioritization, yet their performance compared with manual curation remains insufficiently evaluated. The aim of this study was to evaluate the performance of AI-driven platforms for variant prioritization in a cohort of patients with inborn errors of immunity (IEI) and to compare their strengths and limitations with manual curation.Methods: We analyzed 22 unsolved IEI cases that had previously undergone inconclusive NGS studies. Whole-genome sequencing was performed, and variant prioritization was carried out using two AI-driven platforms -AIMARRVEL and AION (Nostos Genomics)- and by manual curation. Selected variants were classified according to clinical relevance (very high, high, medium, or low), integrating both molecular and phenotypic evidence.Results: Across the cohort, AI platforms efficiently prioritized variants with clear pathogenic features, often reaching the same conclusions as manual curation but in a fraction of the time. One patient (5%) received a conclusive diagnosis (FAM111B), and four patients (18%) carried variants of high clinical relevance, including strong disease-causing candidates in CD247 and SH2B3. Additional medium-relevance variants were identified in 36% of cases, although evidence was insufficient for functional validation. Notably, concordance between AIMARRVEL and AION was limited, particularly for variants of uncertain significance (VUS), reflecting differences in algorithmic weighting of variant features versus clinical phenotype. Both platforms also highlighted potentially novel associations in RUNX1 and TRAF7, underscoring their capacity to extend beyond classical IEI genes.Discussion: Our results show that AI-driven tools are powerful for detecting clearly pathogenic variants and can markedly accelerate the diagnostic process. However, their strong reliance on curated databases, limited incorporation of phenotypic data, and challenges in handling VUS may reduce their effectiveness. Enhancing phenotype integration, expanding annotations (including non-coding regions), and incorporating up-to-date literature could improve their performance. Ultimately, AI tools should complement expert curation, with future models evolving toward integrative approaches that better capture the complexity of human disorders., The author(s) declared that financial support was received for this work and/or its publication. This study was funded by Instituto de Salud Carlos III, grants PI20/00761 and PI23/00161, co-financed by the European Regional Development Fund (ERDF); and by the Jeffrey Modell Foundation. This research is supported by the European Reference Network for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (ERN-RITA). LM acknowledges support from The Swedish Board of Student Finance (CSN); NM-R was supported by grant 2021 FI_B_00296 from Agència de Gestió d’Ajuts Universitaris i de Recerca, Generalitat de Catalunya; and LB-M is supported by an ISCIII postdoctoral fellowship, “Sara Borrell,” CD24/00011, co-financed by the European Union. Some of the samples were analyzed using the AION platform, supported by the AION Research Grant Program (Nostos) awarded to the Translational Immunology Research Group at VHIR. None of the sponsors has been involved in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.